Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Martin-Broto

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
Cancer|March 5, 2020
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupLorenzo D'Ambrosio, Nathan Touati, Jean-Yves Blay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2016
Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma StudyJavier Martin-Broto, Antonio López Pousa, Ramón de Las Peñas, et al.
The Lancet. Oncology|February 19, 2020
Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trialJavier Martin-Broto, Josefina Cruz, Nicolas Penel, et al.
Cancers|March 6, 2021
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective StudyJavier Martínez-Trufero, Luis Miguel De Sande-González, Pablo Luna, et al.
Therapeutic Advances in Medical Oncology|November 6, 2024
Exploratory analysis of immunomodulatory factors identifies L1CAM as a prognostic marker in alveolar soft-part sarcomaJosé L Mondaza-Hernandez, Nadia Hindi, Antonio Fernandez-Serra, et al.
Ebiomedicine|July 17, 2024
Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapySandro Pasquali, Viviana Vallacchi, Luca Lalli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2024
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of VimseltinibHans Gelderblom, Albiruni A Razak, Matthew H Taylor, et al.
Annals of Surgical Oncology|April 15, 2026
ASO Visual Abstract: First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal SarcomasJosé Antonio Gonzalez, Ana Sebio, Javier Martin-Broto, et al.
The Lancet. Oncology|May 14, 2017
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trialAlessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2024
Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG)Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
Cancer|March 5, 2020
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupLorenzo D'Ambrosio, Nathan Touati, Jean-Yves Blay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2016
Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma StudyJavier Martin-Broto, Antonio López Pousa, Ramón de Las Peñas, et al.
The Lancet. Oncology|February 19, 2020
Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trialJavier Martin-Broto, Josefina Cruz, Nicolas Penel, et al.
Cancers|March 6, 2021
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective StudyJavier Martínez-Trufero, Luis Miguel De Sande-González, Pablo Luna, et al.
Therapeutic Advances in Medical Oncology|November 6, 2024
Exploratory analysis of immunomodulatory factors identifies L1CAM as a prognostic marker in alveolar soft-part sarcomaJosé L Mondaza-Hernandez, Nadia Hindi, Antonio Fernandez-Serra, et al.
Ebiomedicine|July 17, 2024
Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapySandro Pasquali, Viviana Vallacchi, Luca Lalli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2024
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of VimseltinibHans Gelderblom, Albiruni A Razak, Matthew H Taylor, et al.
Annals of Surgical Oncology|April 15, 2026
ASO Visual Abstract: First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal SarcomasJosé Antonio Gonzalez, Ana Sebio, Javier Martin-Broto, et al.
The Lancet. Oncology|May 14, 2017
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trialAlessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2024
Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG)Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, et al.
Pageof 12